The present invention relates generally to application of nickel-titanium alloys to medical devices. More precisely, the present invention is directed to cold worked nickel-titanium alloys that have pseudoelastic behavior without a phase transformation or onset of stress-induced martensite as applied to a medical device deployed from a sheath.
Near equi-atomic binary nickel-titanium alloys (nitinol) are known to exhibit “pseudoelastic” behavior when given certain cold working processes or cold working and heat treatment processes following hot working. Generally speaking, “pseudoelasticity” is the capacity of the nickel-titanium alloy to undergo large elastic strains on the order of 8 percent or more when stressed and to substantially fully recover all strain upon removal of the stress. Substantially full recovery is typically understood to be less than 0.5 percent unrecovered strain, also known as permanent set or amnesia.
Pseudoelasticity can be further divided into two subcategories: “linear” pseudoelasticity and “non-linear” pseudoelasticity. “Non-linear” pseudoelasticity is sometimes used by those in the industry synonymously with “superelasticity.”
Linear pseudoelasticity results from cold working only. Non-linear pseudoelasticity results from cold working and subsequent heat treatment. Non-linear pseudoelasticity, in its idealized state, exhibits a relatively flat loading plateau in which a large amount of recoverable strain is possible with very little increase in stress. This flat plateau can be seen in the stress-strain hysteresis curve of the alloy. Linear pseudoelasticity exhibits no such flat plateau. Non-linear pseudoelasticity is known to occur due to a reversible phase transformation from austenite to martensite, the latter more precisely called “stress-induced martensite” (SIM). Linear pseudoelasticity has no such phase transformation associated with it. Further discussions of linear pseudoelasticity can be found in, for example, T. W. Duerig, et al., “Linear superelasticity in Cold-Worked Ni—Ti,” Engineering Aspects of Shape Memory Alloys, pp. 414-19 (1990).
Because of the useful nature of the nickel-titanium alloy, some have attempted to change its properties to solve different design needs. For example, U.S. Pat. No. 6,106,642 to DiCarlo et al. discloses annealing nitinol to achieve improved ductility and other mechanical properties. U.S. Pat. No. 5,876,434 to Flomenblit et al. teaches annealing and deforming nitinol alloy to obtain different stress-strain relationships.
Binary nickel-titanium alloys have been used in the medical field. Many medical device related applications exploit the non-linear pseudoelastic capabilities of nitinol. Examples include: U.S. Pat. Nos. 4,665,906; 5,067,957; 5,190,546; and 5,597,378 to Jervis; and U.S. Pat. Nos. 5,509,923; 5,486,183; 5,632,746; 5,720,754; and 6,004,629 to Middleman, et al.
Yet another application of nickel-titanium alloys is in an embolic protection or filtering device. Such embolic filtering devices and systems are particularly useful when performing balloon angioplasty, stenting procedures, laser angioplasty, or atherectomy in critical vessels, particularly in vessels such as the carotid arteries, where the release of embolic debris into the bloodstream can occlude the flow of oxygenated blood to the brain or other vital organs. Such an occlusion can cause devastating consequences to the patient. While the embolic protection devices and systems are particularly useful in carotid procedures, they are equally useful in conjunction with any vascular interventional procedure in which there is an embolic risk. An embolic protection device that uses superelastic nitinol recently released to the market by the Cordis Corporation is known as the ANGIOGUARD.
What has been needed and heretofore unavailable in the prior art is a medical device that exploits the benefits of linear pseudoelastic nitinol. With the use of linear pseudoelastic nitinol, the mechanical strength of the device is substantially greater per unit strain than a comparable device made of superelastic nitinol. Furthermore, smaller component parts such as struts can be used because of the greater storage of energy available in a linear pseudoelastic nitinol device.
The present invention is generally directed to cold worked nickel-titanium alloys that have linear pseudoelastic behavior without a phase transformation or onset of stress-induced martensite as applied to a medical device having a strut formed body deployed from a sheath.
In one preferred embodiment, the present invention is directed to a medical device for use in a body lumen comprising a body formed from struts, wherein the body includes a cold formed nickel-titanium alloy, and the nickel-titanium alloy is in a martensitic phase when the body is stressed into a first shape and also when the stress to the body is relieved to assume a second shape. The present invention further includes a sheath at least partially enveloping the body in its first shape. The sheath may be used to transport the device to a targeted location in the patient's anatomy, to deploy the device, and to retrieve the device at the end of the procedure.
The raw nitinol for use in the present invention has been cold formed and is further cold worked to set the desired expanded shape. Furthermore, the cold forming and cold working occur below the recrystallization temperature of the nitinol alloy.
During its operation, the linear pseudoelastic nitinol device can be stressed without developing stress-induced martensite in the alloy. Consistent with this behavior, an idealized stress-strain curve of the linear pseudoelastic nitinol does not contain any flat stress plateaus. Furthermore, despite application of stress, the nitinol alloy does not undergo a phase transformation from austenite to martensite or vice versa.
The resulting preferred embodiment device has greater mechanical strength at any given strain as compared to a device made of a standard superelastic nitinol. The stress-strain curve of the present invention linear pseudoelastic nitinol device also possesses more energy storage capacity. As a result, for a given desired performance requirement, the present invention linear pseudoelastic nitinol device allows for smaller struts and consequently a lower profile useful in crossing narrow lesions.
Another advantage is that because the present invention uses linear pseudoelastic nitinol, the underlying alloy can be selected from a broader range of available materials yet still maintain consistent, mechanical properties. In other words, there is less sensitivity to material variations and processing vagaries as compared to superelastic nitinol. In addition, since the linear pseudoelastic nitinol has no transformation from martensite to austenite or vice versa, there is less of an influence by temperature-related effects.
There are many specific applications for the present invention including vena cava filters, septal plugs, just to name a few. One specific application for the present invention is in a filtering device and system for capturing embolic debris in a blood vessel created during the performance of a therapeutic interventional procedure, such as a balloon angioplasty or stenting procedure, in order to prevent the embolic debris from blocking blood vessels downstream from the interventional site. The devices and systems of the present invention are particularly useful while performing an interventional procedure in critical arteries, such as the carotid arteries, in which vital downstream blood vessels can easily become blocked with embolic debris, including the main blood vessels leading to the brain. When used in carotid procedures, the present invention minimizes the potential for a stroke occurring during the procedure. As a result, the present invention provides the physician with a higher degree of confidence that embolic debris is being properly collected and removed from the patient's vasculature during the interventional procedure.
An embolic protection device and system made in accordance with the present invention preferably includes an expandable filter assembly which is affixed to the distal end of a cylindrical shaft, such as a guide wire. The filter assembly includes an expandable strut assembly preferably made from a linear pseudoelastic nitinol, and includes a number of outwardly biased and extending struts that are capable of self-expansion from a contracted or collapsed position to an expanded or deployed position within a patient's vasculature. A filter element made from an embolic capturing media is attached to the expandable strut assembly. The filter element opens from a collapsed configuration to an expanded configuration via the movement of the expandable struts similar to that of an umbrella.
Other features and advantages of the present invention will become more apparent from the following detailed description of the invention when taken in conjunction with the accompanying exemplary drawings.
The present invention is generally directed to cold worked nickel-titanium alloys that have linear'pseudoelastic behavior without a phase transformation or onset of stress-induced martensite as applied to a medical device having a strut formed body deployed from a sheath. Although the present invention is applicable to and contemplates numerous medical devices, for the sake of illustration, the following detail description focuses on an exemplary embodiment involving a filtering device and system for capturing embolic debris in a blood vessel created during the performance of a therapeutic interventional procedure.
In a preferred embodiment, the present invention medical device has a body formed from struts, wherein the body includes a cold formed nickel-titanium alloy, and the nickel-titanium alloy is in a martensitic phase when the body is stressed into a first shape and also when the stress on the body is relieved to assume a second shape. The preferred embodiment further includes a sheath at least partially enveloping the body in its first shape. The sheath may be used to transport the device to a targeted location in the patient's anatomy, to deploy the device, and to retrieve the device at the end of the procedure.
Turning now to the drawings, in which like reference numerals represent like or corresponding elements,
In the side elevational and cross-sectional views of
A balloon angioplasty catheter (not shown) can optionally be introduced within the patient's vasculature in a conventional Seldinger technique through a guiding catheter (not shown). The guide wire 18 is passed through the area of treatment 22 and the dilatation catheter can be advanced over the guide wire 18 within the artery 20 until the balloon portion is appositioned directly in the area of treatment 22. The balloon of the dilatation catheter is inflated, thereby expanding the plaque 24 against the inside wall 26 of the artery 20. This opens the occlusion, expands the artery 20, and reduces the blockage in the vessel caused by the plaque 24.
After the dilatation catheter is removed from the patient's vasculature, a stent 25 (shown in
Any embolic debris 27 that breaks off from the plaque 24 during the interventional procedure is released into the bloodstream. The embolic debris 27 is carried by blood flow (indicated by arrows) and is captured by the deployed, i.e., unfurled, filter element 16 of the filter assembly 12 located downstream from the area of treatment 22. Once the interventional procedure is completed, the filter assembly 12 is collapsed and removed from the patient's vasculature, taking with it all embolic debris 27 trapped within the filter element 16.
One exemplary embodiment of the expandable strut assembly 14 is shown in
The expandable strut assembly 14 includes a proximal end 32 which is optionally rotatably attached to the guide wire 18. A distal end 34 is free to slide longitudinally along the guide wire 18 and can rotate thereabout. The distal end 34 translates along the guide wire 18 whenever the struts 28 move between the expanded and contracted positions. A proximal end 32 includes a short tubular segment or sleeve 36 which has a coil spring formed therein and which acts as a dampening member or element 38. The function of the dampening element 38 is explained below. The distal end 34 of the tubing 30 preferably includes a short segment or sleeve 40 which is slidably and rotatably disposed on the guide wire 18.
The filter element 16 in one preferred embodiment of the invention includes a tapered or cone shaped section 50, as seen in
The short proximal section 52 also functions as a superstructure to which the filter element 16 and the struts 28 of the strut assembly 14 can be adhesively or otherwise affixed. At the opposite end, the filter element 16 has a short distal cylindrical section 54 which is integral with the remaining sections of the filter element and is attached to the distal end 34 of the expandable strut assembly 14.
As best seen in
The guide wire 18 and the restraining sheath 46 have proximal ends (not shown) that extend outside of the patient. From outside the patient, it is possible to manipulate the struts 28 into the expanded position by retracting the restraining sheath 46 via its proximal end to expose the struts 28. Since the struts 28 are self-expanding by nature, the withdrawal of the restraining sheath 46 allows the struts 28 to spring open and the filter element 16 to unfurl into their expanded positions within the artery 20. This is depicted in
The guide wire 18 optionally includes a small sphere 56 affixed thereto. The small sphere 56 is useful during the delivery of the embolic protection device 10 into the patient's vasculature. Specifically, the sphere 56 is approximately as large as the inner diameter of the restraining sheath 46 and is effectively used as a nose cone. The nose cone prevents possible “snowplowing” of the embolic protection device 10 as it is delivered through the patient's arteries.
When the embolic protection device 10 is to be removed from the patient's vasculature, an optional recovery sheath 48 is used to collapse and recover the filter assembly 12, as shown in
The collapse of the expandable strut assembly 14 can be accomplished by holding the guide wire 18 and moving the proximal end (not shown) of the recovery sheath 48 forward, which moves the distal end 47 of the sheath 48 over the struts 28. Alternatively, the recovery sheath 48 can be held stationary while the proximal end of the guide wire 18 is retracted back to pull the entire filter assembly 12 into the sheath 48. Upon collapse of the filter assembly 12, any embolic debris 27 generated and entering the bloodstream during the interventional procedure remains trapped inside the filter element 16 and is withdrawn from the bloodstream when the embolic protection device 10 is removed from the patient's vasculature.
The number of struts 28 formed on the expandable strut assembly 14 can be any number which provides sufficient expandability within the artery to properly deploy and maintain the filter element 16 in place. In the embodiment shown in
When the precise pattern is cut into the tubing 30, a sleeve 36 which forms the proximal end 32 may optionally be formed into a helical coil as shown in
Subsequently, the laser cut nitinol tubing 30 is preferably cold formed and specifically cold worked with no heat treatment such that it remains in the fully martensitic state. The cold working proceeds only at temperatures below the recrystallization temperature of the nitinol alloy. Next, the laser-cut nitinol tubing 30 is cold worked to its desired expanded size. The desired expanded size is thus imparted or set into the laser cut tube.
Importantly, the laser-cut nitinol tubing 30 is not heat treated to prevent generation of any loading or unloading plateaus in the stress-strain curve. In an alternative embodiment, the nitinol tubing may undergo heat treating for only very limited durations at low temperatures. The present invention recognizes that a significant difference between linear pseudoelasticity and non-linear pseudoelasticity is the absence or presence, respectively, of stress-induced martensite. It also recognizes that in order to set a particular shape in nitinol, the nitinol must be heat treated at a relatively high temperature for a short period of time. Under normal circumstances, this material would then exhibit non-linear pseudoelasticity and therefore would undergo a reversible phase transformation from austenite to martensite. When setting a shape under standard conditions, for example, 550 degrees C. for 5 minutes, the nitinol exhibits essentially no springback; that is, its unconstrained shape after heat treatment is nearly identical to its constrained shape during heat treatment. The nitinol does not spring back to its original shape prior to heat treatment. At the other extreme, linear pseudoelastic nitinol with no heat treatment has 100 percent springback and always returns to its original, cold worked shape.
Springback is a continuous function between no heat treatment (100 percent springback) and ideal shape setting heat treatment (approximately zero percent springback). From an engineering perspective for design of nitinol based pseudoelastic devices, less springback is more favorable than more springback. However, in some circumstances, linear pseudoelasticity may be preferable to non-linear pseudoelasticity. Therefore, the present invention, in addition to contemplating cold-worked only nitinol, addresses that regime of heat treatment temperatures and times within which springback is adequately minimized to successfully impart a desired shape to the nitinol structure and within which the nitinol does not develop a stable and reversible martensitic phase.
In the preferred embodiment of the present invention, to achieve the linear pseudoelastic behavior, the binary nickel-titanium tubing has approximately 55.8 atomic percent nickel. The tubing must contain a minimum of approximately 38 percent cold working when measured by the reduction in cross-sectional area, and there is not to be any heat treatment following final cold reduction. As to the alternative embodiment, the present invention contemplates accumulated heat treatment of the tubing of up to 300 degrees C. for up to 5 minutes. Under ideal conditions, these process parameters should adequately ensure that the nitinol remains martensitic without a phase change under stress.
To illustrate the foregoing points,
In
In curve A, when stress is applied to a specimen of a metal such as nitinol exhibiting non-linear pseudoelastic characteristics at a temperature at or above that which the transformation of the martensitic phase to the austenitic phase is complete, the specimen deforms elastically until it reaches a particular stress level where the alloy then undergoes a stress-induced phase transformation from the austenitic phase to the martensitic phase (i.e., the stress-induced martensite phase). As the phase transformation progresses, the alloy undergoes significant increases in strain with little or no corresponding increases in stress. On curve A this is represented by upper, nearly flat stress plateau at approximately 70 to 80 ksi. The strain increases while the stress remains essentially constant until the transformation of the austenitic phase to the martensitic phase is complete. Thereafter, further increase in stress is necessary to cause further deformation. The martensitic metal first yields elastically upon the application of additional stress and then plastically with permanent residual deformation (not shown).
If the load on the specimen is removed before any permanent deformation has occurred, the martensite specimen elastically recovers and transforms back to the austenitic phase. The reduction in stress first causes a decrease in strain. As stress reduction reaches the level at which the martensitic phase transforms back into the austenitic phase, the stress level in the specimen remains essentially constant (but less than the constant stress level at which the austenitic crystalline structure transforms to the martensitic crystalline structure until the transformation back to the austenitic phase is complete); i.e., there is significant recovery in strain with only negligible corresponding stress reduction. This is represented in curve A by the lower stress plateau at about 20 ksi.
After the transformation back to austenite is complete, further stress reduction results in elastic strain reduction. This ability to incur significant strain at relatively constant stress upon the application of a load and to recover from the deformation upon the removal of the load is commonly referred to as non-linear pseudoelasticity (or superelasticity).
As apparent from comparing curve B to curve A in
As mentioned above, the present invention medical device uses preferably a binary nickel-titanium alloy. In an alternative embodiment, however, the nickel-titanium may be alloyed with a ternary element such as palladium, platinum, chromium, iron, cobalt, vanadium, manganese, boron, copper, aluminum, tungsten, tantalum, or zirconium.
While the present invention has been illustrated and described herein in terms of linear pseudoelastic nitinol filter assembly of an embolic protection device and its delivery system, it is apparent to those skilled in the art that the present invention can be used in other instances. Other modifications and improvements may be made without departing from the scope of the present invention.
Number | Name | Date | Kind |
---|---|---|---|
2738294 | Spence | Mar 1956 | A |
2768271 | Meredith | Oct 1956 | A |
3558369 | Wang et al. | Jan 1971 | A |
3605725 | Bentov | Sep 1971 | A |
3620212 | Fannon et al. | Nov 1971 | A |
3753700 | Harrison et al. | Aug 1973 | A |
3890977 | Wilson | Jun 1975 | A |
3953253 | Clark | Apr 1976 | A |
4019899 | Negishi et al. | Apr 1977 | A |
4037324 | Andreasen | Jul 1977 | A |
4069226 | Kablaoui et al. | Jan 1978 | A |
4144057 | Melton et al. | Mar 1979 | A |
4233690 | Akins | Nov 1980 | A |
4283233 | Goldstein et al. | Aug 1981 | A |
4304613 | Wang et al. | Dec 1981 | A |
4310354 | Fountain et al. | Jan 1982 | A |
4323071 | Simpson et al. | Apr 1982 | A |
4386971 | Melton et al. | Jun 1983 | A |
4390599 | Broyles | Jun 1983 | A |
4411655 | Schreck | Oct 1983 | A |
4425908 | Simon | Jan 1984 | A |
4427000 | Ueda | Jan 1984 | A |
4439185 | Lundquist | Mar 1984 | A |
4503569 | Dotter | Mar 1985 | A |
4505767 | Quin | Mar 1985 | A |
4512338 | Balko et al. | Apr 1985 | A |
4516972 | Samson | May 1985 | A |
4518444 | Albrecht et al. | May 1985 | A |
4533411 | Melton | Aug 1985 | A |
4538622 | Samson et al. | Sep 1985 | A |
4554929 | Samson et al. | Nov 1985 | A |
4565589 | Harrison | Jan 1986 | A |
4580568 | Gianturco | Apr 1986 | A |
4582181 | Samson | Apr 1986 | A |
4616652 | Simpson | Oct 1986 | A |
4631094 | Simpson et al. | Dec 1986 | A |
4638805 | Powell | Jan 1987 | A |
4665906 | Jervis | May 1987 | A |
4740253 | Simpson et al. | Apr 1988 | A |
4748986 | Morrison et al. | Jun 1988 | A |
4768507 | Fischell et al. | Sep 1988 | A |
4770725 | Simpson et al. | Sep 1988 | A |
4776844 | Ueda | Oct 1988 | A |
4793350 | Mar et al. | Dec 1988 | A |
4827941 | Taylor et al. | May 1989 | A |
4846573 | Taylor et al. | Jul 1989 | A |
4856516 | Hillstead | Aug 1989 | A |
4865663 | Tuominen et al. | Sep 1989 | A |
4875489 | Messner et al. | Oct 1989 | A |
4881981 | Thoma et al. | Nov 1989 | A |
4894100 | Yamauchi et al. | Jan 1990 | A |
4925445 | Sakamoto et al. | May 1990 | A |
4935068 | Duerig | Jun 1990 | A |
4943326 | Ozawa et al. | Jul 1990 | A |
4969890 | Sugita et al. | Nov 1990 | A |
4984581 | Stice | Jan 1991 | A |
4991602 | Amplatz et al. | Feb 1991 | A |
5001446 | Tsuji et al. | Mar 1991 | A |
5002563 | Pyka et al. | Mar 1991 | A |
5025799 | Wilson | Jun 1991 | A |
5044947 | Sachdeva et al. | Sep 1991 | A |
5067489 | Lind | Nov 1991 | A |
5067957 | Jervis | Nov 1991 | A |
5069226 | Yamauchi et al. | Dec 1991 | A |
5092877 | Pinchuk | Mar 1992 | A |
5108523 | Peterseim et al. | Apr 1992 | A |
5114504 | AbuJudom, II et al. | May 1992 | A |
5117838 | Palmer et al. | Jun 1992 | A |
5120308 | Hess | Jun 1992 | A |
5135503 | Abrams | Aug 1992 | A |
5143085 | Wilson | Sep 1992 | A |
5171383 | Sagaye et al. | Dec 1992 | A |
5188621 | Samson | Feb 1993 | A |
5190546 | Jervis | Mar 1993 | A |
5201901 | Harada et al. | Apr 1993 | A |
5230348 | Ishibe et al. | Jul 1993 | A |
5230349 | Langberg | Jul 1993 | A |
5234458 | Metais | Aug 1993 | A |
5238004 | Sahatjian et al. | Aug 1993 | A |
5243996 | Hall | Sep 1993 | A |
5271975 | Solano | Dec 1993 | A |
5292331 | Boneau | Mar 1994 | A |
5318527 | Hyde et al. | Jun 1994 | A |
5341815 | Cofone et al. | Aug 1994 | A |
5341818 | Abrams et al. | Aug 1994 | A |
5345937 | Middleman et al. | Sep 1994 | A |
5345945 | Hodgson et al. | Sep 1994 | A |
5350398 | Pavcnik et al. | Sep 1994 | A |
5350419 | Bendel et al. | Sep 1994 | A |
5354623 | Hall | Oct 1994 | A |
5368049 | Raman et al. | Nov 1994 | A |
5411476 | Abrams et al. | May 1995 | A |
5458615 | Klemm et al. | Oct 1995 | A |
5465717 | Imran et al. | Nov 1995 | A |
5486183 | Middleman et al. | Jan 1996 | A |
5507766 | Kugo et al. | Apr 1996 | A |
5509923 | Middleman et al. | Apr 1996 | A |
5514154 | Lau et al. | May 1996 | A |
5534007 | St. Germain et al. | Jul 1996 | A |
5549626 | Miller et al. | Aug 1996 | A |
5562641 | Flomenblit et al. | Oct 1996 | A |
5569295 | Lam | Oct 1996 | A |
5573520 | Schwartz et al. | Nov 1996 | A |
5597378 | Jervis | Jan 1997 | A |
5607444 | Lam | Mar 1997 | A |
5611874 | Zadno-Azizi et al. | Mar 1997 | A |
5630840 | Mayer | May 1997 | A |
5632746 | Middleman et al. | May 1997 | A |
5637089 | Abrams et al. | Jun 1997 | A |
5641364 | Goldberg et al. | Jun 1997 | A |
5643312 | Fischell et al. | Jul 1997 | A |
5667522 | Flomenblit et al. | Sep 1997 | A |
5690644 | Yurek et al. | Nov 1997 | A |
5695111 | Nanis et al. | Dec 1997 | A |
5713853 | Clark et al. | Feb 1998 | A |
5720300 | Fagan et al. | Feb 1998 | A |
5720754 | Middleman et al. | Feb 1998 | A |
5749370 | Brooks et al. | May 1998 | A |
5749870 | Gloth et al. | May 1998 | A |
5749879 | Middleman et al. | May 1998 | A |
5759192 | Saunders | Jun 1998 | A |
5766218 | Arnott | Jun 1998 | A |
5776114 | Frantzen et al. | Jul 1998 | A |
5780807 | Saunders | Jul 1998 | A |
5810874 | Lefebvre | Sep 1998 | A |
5820628 | Middleman et al. | Oct 1998 | A |
5833631 | Nguyen | Nov 1998 | A |
5836966 | St. Germain | Nov 1998 | A |
5836968 | Simon et al. | Nov 1998 | A |
5837313 | Ding et al. | Nov 1998 | A |
5843244 | Pelton et al. | Dec 1998 | A |
5865768 | Orr | Feb 1999 | A |
5876356 | Viera et al. | Mar 1999 | A |
5876434 | Flomenblit et al. | Mar 1999 | A |
5885381 | Mitose et al. | Mar 1999 | A |
5891191 | Stinson | Apr 1999 | A |
5902317 | Kleshinski et al. | May 1999 | A |
5904690 | Middleman et al. | May 1999 | A |
5907893 | Zadno-Azizi et al. | Jun 1999 | A |
5910154 | Tsugita et al. | Jun 1999 | A |
5911734 | Tsugita et al. | Jun 1999 | A |
5922393 | Jayaraman | Jul 1999 | A |
5927345 | Samson | Jul 1999 | A |
5931819 | Fariabi | Aug 1999 | A |
5951793 | Mitose et al. | Sep 1999 | A |
5964770 | Flomenblit et al. | Oct 1999 | A |
5976153 | Fischell et al. | Nov 1999 | A |
5980471 | Jafari | Nov 1999 | A |
5980566 | Alt et al. | Nov 1999 | A |
5989280 | Euteneuer et al. | Nov 1999 | A |
6001123 | Lau | Dec 1999 | A |
6004330 | Middleman et al. | Dec 1999 | A |
6004629 | Madigan | Dec 1999 | A |
6007558 | Ravenscroft et al. | Dec 1999 | A |
RE36628 | Sagae et al. | Mar 2000 | E |
6051021 | Frid | Apr 2000 | A |
6053992 | Wu et al. | Apr 2000 | A |
6059738 | Stoltze et al. | May 2000 | A |
6059810 | Brown et al. | May 2000 | A |
6066149 | Samson et al. | May 2000 | A |
6068610 | Ellis et al. | May 2000 | A |
6068623 | Zadno-Azizi et al. | May 2000 | A |
6077287 | Taylor et al. | Jun 2000 | A |
6077295 | Limon et al. | Jun 2000 | A |
6086610 | Duerig et al. | Jul 2000 | A |
6096175 | Roth | Aug 2000 | A |
6099549 | Bosma et al. | Aug 2000 | A |
6106642 | DiCarlo et al. | Aug 2000 | A |
6129739 | Khosravi | Oct 2000 | A |
6131266 | Saunders | Oct 2000 | A |
6137060 | Avellanet | Oct 2000 | A |
6152946 | Broome et al. | Nov 2000 | A |
6165140 | Ferrera | Dec 2000 | A |
6165195 | Wilson et al. | Dec 2000 | A |
6165292 | Abrams et al. | Dec 2000 | A |
6168571 | Solar et al. | Jan 2001 | B1 |
6171327 | Daniel et al. | Jan 2001 | B1 |
6171334 | Cox | Jan 2001 | B1 |
6179859 | Bates et al. | Jan 2001 | B1 |
6183409 | Armini | Feb 2001 | B1 |
6190332 | Muni et al. | Feb 2001 | B1 |
6210312 | Nagy | Apr 2001 | B1 |
6217567 | Zadno-Azizi et al. | Apr 2001 | B1 |
6217589 | McAlister | Apr 2001 | B1 |
6245103 | Stinson | Jun 2001 | B1 |
6257513 | Cockerham et al. | Jul 2001 | B1 |
6264671 | Stack et al. | Jul 2001 | B1 |
6277139 | Levinson et al. | Aug 2001 | B1 |
6280539 | Abrams et al. | Aug 2001 | B1 |
6287336 | Globerman et al. | Sep 2001 | B1 |
6306141 | Jervis | Oct 2001 | B1 |
6312454 | Stöckel et al. | Nov 2001 | B1 |
6312455 | Duerig et al. | Nov 2001 | B2 |
6322847 | Zhong et al. | Nov 2001 | B1 |
6325824 | Limon | Dec 2001 | B2 |
6329069 | Azizi et al. | Dec 2001 | B1 |
6346116 | Brooks et al. | Feb 2002 | B1 |
6352515 | Anderson et al. | Mar 2002 | B1 |
6358556 | Ding et al. | Mar 2002 | B1 |
6371970 | Khosravi et al. | Apr 2002 | B1 |
6375458 | Moorleghem et al. | Apr 2002 | B1 |
6375628 | Zadno-Azizi et al. | Apr 2002 | B1 |
6375629 | Muni et al. | Apr 2002 | B1 |
6379369 | Abrams et al. | Apr 2002 | B1 |
6380457 | Yurek et al. | Apr 2002 | B1 |
6390993 | Cornish et al. | May 2002 | B1 |
6391502 | Anderson et al. | May 2002 | B1 |
6402761 | McAlister | Jun 2002 | B2 |
6419692 | Yang et al. | Jul 2002 | B1 |
6419693 | Fariabi | Jul 2002 | B1 |
6428634 | Besselink et al. | Aug 2002 | B1 |
6432116 | Callister et al. | Aug 2002 | B1 |
6447523 | Middleman et al. | Sep 2002 | B1 |
6451047 | McCrea et al. | Sep 2002 | B2 |
6451052 | Burmeister et al. | Sep 2002 | B1 |
6458145 | Ravenscroft et al. | Oct 2002 | B1 |
6461453 | Abrams et al. | Oct 2002 | B1 |
6468230 | Muni et al. | Oct 2002 | B2 |
6500182 | Foster | Dec 2002 | B2 |
6508803 | Horikawa et al. | Jan 2003 | B1 |
6509094 | Shah et al. | Jan 2003 | B1 |
6533805 | Jervis | Mar 2003 | B1 |
6554848 | Boylan et al. | Apr 2003 | B2 |
6558405 | McInnes | May 2003 | B1 |
6572646 | Boylan et al. | Jun 2003 | B1 |
6582461 | Burmeister et al. | Jun 2003 | B1 |
6592559 | Pakter et al. | Jul 2003 | B1 |
6592570 | Abrams et al. | Jul 2003 | B2 |
6602208 | Jafari | Aug 2003 | B2 |
6602228 | Nanis et al. | Aug 2003 | B2 |
6602272 | Boylan et al. | Aug 2003 | B2 |
6626937 | Cox | Sep 2003 | B1 |
6638372 | Abrams | Oct 2003 | B1 |
6682608 | Abrams et al. | Jan 2004 | B2 |
6706053 | Boylan et al. | Mar 2004 | B1 |
6755855 | Yurek et al. | Jun 2004 | B2 |
6824560 | Pelton | Nov 2004 | B2 |
6830638 | Boylan et al. | Dec 2004 | B2 |
6855161 | Boylan et al. | Feb 2005 | B2 |
7037320 | Brady | May 2006 | B2 |
7128757 | Boylan et al. | Oct 2006 | B2 |
7244319 | Abrams et al. | Jul 2007 | B2 |
7258753 | Abrams et al. | Aug 2007 | B2 |
20010007953 | Duerig et al. | Jul 2001 | A1 |
20010039446 | Edwin et al. | Nov 2001 | A1 |
20010039449 | Johnson et al. | Nov 2001 | A1 |
20010047202 | Slaikeu et al. | Nov 2001 | A1 |
20010049549 | Boylan et al. | Dec 2001 | A1 |
20020010481 | Jayaraman et al. | Jan 2002 | A1 |
20020046785 | Abrams et al. | Apr 2002 | A1 |
20020052627 | Boylan et al. | May 2002 | A1 |
20020062092 | Muni et al. | May 2002 | A1 |
20020068954 | Foster | Jun 2002 | A1 |
20020082681 | Boylan et al. | Jun 2002 | A1 |
20020087099 | Nanis et al. | Jul 2002 | A1 |
20020121316 | Abrams et al. | Sep 2002 | A1 |
20020138129 | Armstrong et al. | Sep 2002 | A1 |
20020193824 | Boylan et al. | Dec 2002 | A1 |
20020193827 | McGuckin, Jr. et al. | Dec 2002 | A1 |
20030004536 | Boylan et al. | Jan 2003 | A1 |
20030036794 | Ragheb et al. | Feb 2003 | A1 |
20030040772 | Hyodoh et al. | Feb 2003 | A1 |
20030055449 | Lee et al. | Mar 2003 | A1 |
20030055484 | Lau et al. | Mar 2003 | A1 |
20030069492 | Abrams et al. | Apr 2003 | A1 |
20030069521 | Reynolds et al. | Apr 2003 | A1 |
20030120181 | Toma et al. | Jun 2003 | A1 |
20030127158 | Abrams et al. | Jul 2003 | A1 |
20030158575 | Boylan et al. | Aug 2003 | A1 |
20030199920 | Boylan et al. | Oct 2003 | A1 |
20040084115 | Abrams et al. | May 2004 | A1 |
20040093009 | Denison et al. | May 2004 | A1 |
20040158281 | Boylan et al. | Aug 2004 | A1 |
20040172055 | Huter et al. | Sep 2004 | A1 |
20040220608 | D'Aquanni et al. | Nov 2004 | A1 |
20050038500 | Boylan et al. | Feb 2005 | A1 |
20060086440 | Boylan et al. | Apr 2006 | A1 |
20060212068 | Boylan | Sep 2006 | A1 |
20070233179 | Brady et al. | Oct 2007 | A1 |
20070239259 | Boylan | Oct 2007 | A1 |
20070249965 | Abrams et al. | Oct 2007 | A1 |
20080027532 | Boylan et al. | Jan 2008 | A1 |
20090098013 | Boylan et al. | Apr 2009 | A1 |
20090248130 | Boylan | Oct 2009 | A1 |
20100125329 | Lin et al. | May 2010 | A1 |
Number | Date | Country |
---|---|---|
0145166 | Jun 1985 | EP |
0199715 | Oct 1986 | EP |
0340304 | Nov 1989 | EP |
0395098 | Oct 1990 | EP |
0480427 | Apr 1992 | EP |
0484805 | May 1992 | EP |
0491349 | Jun 1992 | EP |
0515078 | Nov 1992 | EP |
0520073 | Dec 1992 | EP |
0550258 | Jul 1993 | EP |
0550288 | Jul 1993 | EP |
0569166 | Nov 1993 | EP |
0791340 | Aug 1997 | EP |
0804934 | Nov 1997 | EP |
0806220 | Nov 1997 | EP |
0812928 | Dec 1997 | EP |
0815803 | Jan 1998 | EP |
0 873 734 | Oct 1998 | EP |
0879614 | Nov 1998 | EP |
0968688 | Jan 2000 | EP |
1027906 | Aug 2000 | EP |
1426071 | Jun 2004 | EP |
44-31704 | Dec 1969 | JP |
44-32286 | Dec 1969 | JP |
53-12759 | Feb 1978 | JP |
55-164304 | Dec 1980 | JP |
57-89859 | Jun 1982 | JP |
58-161746 | Sep 1983 | JP |
60-145155 | Jul 1985 | JP |
60-138547 | Sep 1985 | JP |
60-248856 | Dec 1985 | JP |
61-84361 | Apr 1986 | JP |
61-183455 | Aug 1986 | JP |
62-199757 | Sep 1987 | JP |
62-199758 | Sep 1987 | JP |
62-235449 | Oct 1987 | JP |
63-171570 | Jul 1988 | JP |
64-49571 | Feb 1989 | JP |
1-124473 | May 1989 | JP |
1-242763 | Sep 1989 | JP |
2252467 | Oct 1990 | JP |
2289265 | Nov 1990 | JP |
2289266 | Nov 1990 | JP |
4-9162 | Jan 1992 | JP |
50-19512 | Jan 1993 | JP |
5-092044 | Apr 1993 | JP |
6-83726 | Mar 1994 | JP |
61-08431 | Apr 1994 | JP |
09-215753 | Aug 1997 | JP |
11-76420 | Mar 1999 | JP |
2000-140124 | May 2000 | JP |
03-295562 | Oct 2003 | JP |
4-292174 | Oct 2004 | JP |
WO 8910088 | Nov 1989 | WO |
WO 8912175 | Dec 1989 | WO |
WO 9013329 | Nov 1990 | WO |
WO 9115152 | Oct 1991 | WO |
WO 9205828 | Apr 1992 | WO |
WO 9319803 | Oct 1993 | WO |
WO 9519800 | Jul 1995 | WO |
WO 9724978 | Jul 1997 | WO |
WO 9738747 | Oct 1997 | WO |
WO 9820801 | May 1998 | WO |
WO 9820810 | May 1998 | WO |
WO 9932051 | Jul 1999 | WO |
WO 9944542 | Sep 1999 | WO |
WO 0004846 | Feb 2000 | WO |
WO 0049970 | Aug 2000 | WO |
WO 0067665 | Nov 2000 | WO |
WO 0067668 | Nov 2000 | WO |
WO 0069359 | Nov 2000 | WO |
WO 0139695 | Jun 2001 | WO |
WO 0141859 | Jun 2001 | WO |
WO 0182830 | Nov 2001 | WO |
WO 0236841 | May 2002 | WO |
WO 02051462 | Jul 2002 | WO |
WO 02102281 | Dec 2002 | WO |
WO 03002166 | Jan 2003 | WO |
WO 03028796 | Apr 2003 | WO |
WO 03097148 | Nov 2003 | WO |
WO 2004033016 | Apr 2004 | WO |
WO 2004098458 | Nov 2004 | WO |
WO 2005102407 | Nov 2005 | WO |
WO 2006081011 | Aug 2006 | WO |